Sylvania Platinum (SLP) Competitors

Sylvania Platinum (LON:SLP) and Dr. Martens (LON:DOCS) are both small-cap computer software companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Is SLP or DOCS more profitable?

Sylvania Platinum has a net margin of 8.55% compared to Dr. Martens' net margin of 7.89%. Dr. Martens' return on equity of 18.91% beat Sylvania Platinum's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sylvania Platinum	8.55%	2.82%	1.69%
Dr. Martens	7.89%	18.91%	8.12%

Is SLP or DOCS a better dividend stock?

Sylvania Platinum pays an annual dividend of GBX 2 per share and has a dividend yield of 2.8%. Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 3.3%. Sylvania Platinum pays out 93.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Dr. Martens is clearly the better dividend stock, given its higher yield and lower payout ratio.

Do insiders & institutionals believe in SLP or DOCS?

17.8% of Sylvania Platinum shares are held by institutional investors. Comparatively, 69.5% of Dr. Martens shares are held by institutional investors. 12.2% of Sylvania Platinum shares are held by company insiders. Comparatively, 4.4% of Dr. Martens shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, SLP or DOCS?

Sylvania Platinum has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500. Comparatively, Dr. Martens has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500.

Which has better earnings & valuation, SLP or DOCS?

Dr. Martens has higher revenue and earnings than Sylvania Platinum. Dr. Martens is trading at a lower price-to-earnings ratio than Sylvania Platinum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sylvania Platinum	£99.97M	2.31	£8.54M	£2.13	33.56
Dr. Martens	£874.20M	1.01	£68.97M	£7.05	12.86

Do analysts rate SLP or DOCS?

Sylvania Platinum presently has a consensus target price of GBX 93, suggesting a potential upside of 29.85%. Dr. Martens has a consensus target price of GBX 6,000, suggesting a potential upside of 6,513.98%. Given Dr. Martens' higher possible upside, analysts clearly believe Dr. Martens is more favorable than Sylvania Platinum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sylvania Platinum	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dr. Martens	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the media favor SLP or DOCS?

In the previous week, Dr. Martens had 2 more articles in the media than Sylvania Platinum. MarketBeat recorded 2 mentions for Dr. Martens and 0 mentions for Sylvania Platinum. Dr. Martens' average media sentiment score of 0.49 beat Sylvania Platinum's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the news media.

Company	Overall Sentiment
Sylvania Platinum	Neutral
Dr. Martens	Neutral

Summary

Dr. Martens beats Sylvania Platinum on 11 of the 17 factors compared between the two stocks.